# Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

> **NCT01445379** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 33 (actual)

## Conditions studied

- Sarcoma
- Wilm's Tumor
- Lymphoma
- Neuroblastoma

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT01445379
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-01
- **Primary completion:** 2014-04-18
- **Final completion:** 2015-11-13
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01445379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01445379, "Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01445379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*